Table 1 displays the recommended adult daily dosage of XELJANZ and XELJANZ XR and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors, in patients with moderate or severe renal impairment (including but not limited to those with severe insufficiency who are undergoing hemodialysis) or moderate hepatic impairment, with lymphopenia, neutropenia, or anemia.
XELJANZ tablet | XELJANZ XR extended-release tablet | |
---|---|---|
| ||
Adult patients | 5 mg twice daily | 11 mg once daily |
Patients receiving:
[see Drug Interactions (7)] | 5 mg once daily | Reduce to XELJANZ 5 mg once daily |
Patients with:
| 5 mg once daily | Reduce to XELJANZ 5 mg once daily |
For patients undergoing hemodialysis, dose should be administered after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended in patients after dialysis. | ||
Patients with lymphocyte count less than 500 cells/mm3, confirmed by repeat testing | Discontinue dosing. | |
Patients with ANC 500 to 1000 cells/mm3 | Interrupt dosing. | Interrupt dosing. |
Patients with ANC less than 500 cells/mm3 | Discontinue dosing. | |
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL | Interrupt dosing until hemoglobin values have normalized. |
Table 2 displays the recommended adult daily dosage of XELJANZ/XELJANZ XR and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors, with moderate or severe renal impairment (including but not limited to those with severe insufficiency who are undergoing hemodialysis) or moderate hepatic impairment, with lymphopenia, neutropenia or anemia.
XELJANZ tablet | XELJANZ XR extended-release tablet | |
---|---|---|
| ||
Adult patients | Induction: 10 mg twice daily for at least 8 weeks [see Clinical Studies (14.4)]; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 10 mg twice daily for a maximum of 16 weeks. Discontinue 10 mg twice daily after 16 weeks if adequate therapeutic response is not achieved.
| Induction: 22 mg once daily for at least 8 weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 22 mg once daily for a maximum of 16 weeks. Discontinue 22 mg once daily after 16 weeks if adequate therapeutic response is not achieved.
|
Patients receiving:
[see Drug Interactions (7)] | If taking 10 mg twice daily, reduce to 5 mg twice daily.
| If taking 22 mg once daily, reduce to 11 mg once daily.
|
Patients with:
| If taking 10 mg twice daily, reduce to 5 mg twice daily.
| If taking 22 mg once daily, reduce to 11 mg once daily.
|
For patients undergoing hemodialysis, dose should be administered after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended in patients after dialysis. | ||
Patients with lymphocyte count less than 500 cells/mm3, confirmed by repeat testing | Discontinue dosing. | |
Patients with ANC 500 to 1000 cells/mm3 | If taking 10 mg twice daily, reduce to 5 mg twice daily. When ANC is greater than 1000, increase to 10 mg twice daily based on clinical response.
| If taking 22 mg once daily, reduce to 11 mg once daily. When ANC is greater than 1000, increase to 22 mg once daily based on clinical response.
|
Patients with ANC less than 500 cells/mm3 | Discontinue dosing. | |
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL | Interrupt dosing until hemoglobin values have normalized. |
Switching from XELJANZ Tablets to XELJANZ XR Extended-Release Tablets
Patients treated with XELJANZ 5 mg tablets twice daily may be switched to XELJANZ XR extended-release tablets 11 mg once daily the day following the last dose of XELJANZ tablets 5 mg. Patients treated with XELJANZ 10 mg tablets twice daily may be switched to XELJANZ XR extended-release tablets 22 mg once daily the day following the last dose of XELJANZ 10 mg.
Table 3 displays the recommended body weight-based dosages for XELJANZ tablets/XELJANZ Oral Solution and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors [see Drug Interactions (7)], in patients with moderate or severe renal impairment, including but not limited to those undergoing hemodialysis [see Use in Specific Populations (8.7)], with moderate hepatic impairment [see Use in Specific Populations (8.8)], with lymphopenia, neutropenia, or anemia.
XELJANZ tablets/XELJANZ Oral Solution | |
---|---|
pcJIA patients |
|
Patients receiving:
[see Drug Interactions (7)] | If taking 3.2 mg twice daily, reduce to 3.2 mg once daily.
|
Patients with:
| If taking 3.2 mg twice daily, reduce to 3.2 mg once daily.
|
Patients with lymphocyte count less than 500 cells/mm3, confirmed by repeat testing | Discontinue dosing. |
Patients with ANC 500 to 1000 cells/mm3 | Interrupt dosing until ANC is greater than 1000 cells/mm3. |
Patients with ANC less than 500 cells/mm3 | Discontinue dosing. |
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL | Interrupt dosing until hemoglobin values have normalized. |
Administer XELJANZ Oral Solution using the included press-in bottle adapter and oral dosing syringe [see Instructions for Use].
Table 1 displays the recommended adult daily dosage of XELJANZ and XELJANZ XR and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors, in patients with moderate or severe renal impairment (including but not limited to those with severe insufficiency who are undergoing hemodialysis) or moderate hepatic impairment, with lymphopenia, neutropenia, or anemia.
XELJANZ tablet | XELJANZ XR extended-release tablet | |
---|---|---|
| ||
Adult patients | 5 mg twice daily | 11 mg once daily |
Patients receiving:
[see Drug Interactions (7)] | 5 mg once daily | Reduce to XELJANZ 5 mg once daily |
Patients with:
| 5 mg once daily | Reduce to XELJANZ 5 mg once daily |
For patients undergoing hemodialysis, dose should be administered after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended in patients after dialysis. | ||
Patients with lymphocyte count less than 500 cells/mm3, confirmed by repeat testing | Discontinue dosing. | |
Patients with ANC 500 to 1000 cells/mm3 | Interrupt dosing. | Interrupt dosing. |
Patients with ANC less than 500 cells/mm3 | Discontinue dosing. | |
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL | Interrupt dosing until hemoglobin values have normalized. |
Table 2 displays the recommended adult daily dosage of XELJANZ/XELJANZ XR and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors, with moderate or severe renal impairment (including but not limited to those with severe insufficiency who are undergoing hemodialysis) or moderate hepatic impairment, with lymphopenia, neutropenia or anemia.
XELJANZ tablet | XELJANZ XR extended-release tablet | |
---|---|---|
| ||
Adult patients | Induction: 10 mg twice daily for at least 8 weeks [see Clinical Studies (14.4)]; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 10 mg twice daily for a maximum of 16 weeks. Discontinue 10 mg twice daily after 16 weeks if adequate therapeutic response is not achieved.
| Induction: 22 mg once daily for at least 8 weeks; evaluate patients and transition to maintenance therapy depending on therapeutic response. If needed continue 22 mg once daily for a maximum of 16 weeks. Discontinue 22 mg once daily after 16 weeks if adequate therapeutic response is not achieved.
|
Patients receiving:
[see Drug Interactions (7)] | If taking 10 mg twice daily, reduce to 5 mg twice daily.
| If taking 22 mg once daily, reduce to 11 mg once daily.
|
Patients with:
| If taking 10 mg twice daily, reduce to 5 mg twice daily.
| If taking 22 mg once daily, reduce to 11 mg once daily.
|
For patients undergoing hemodialysis, dose should be administered after the dialysis session on dialysis days. If a dose was taken before the dialysis procedure, supplemental doses are not recommended in patients after dialysis. | ||
Patients with lymphocyte count less than 500 cells/mm3, confirmed by repeat testing | Discontinue dosing. | |
Patients with ANC 500 to 1000 cells/mm3 | If taking 10 mg twice daily, reduce to 5 mg twice daily. When ANC is greater than 1000, increase to 10 mg twice daily based on clinical response.
| If taking 22 mg once daily, reduce to 11 mg once daily. When ANC is greater than 1000, increase to 22 mg once daily based on clinical response.
|
Patients with ANC less than 500 cells/mm3 | Discontinue dosing. | |
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL | Interrupt dosing until hemoglobin values have normalized. |
Switching from XELJANZ Tablets to XELJANZ XR Extended-Release Tablets
Patients treated with XELJANZ 5 mg tablets twice daily may be switched to XELJANZ XR extended-release tablets 11 mg once daily the day following the last dose of XELJANZ tablets 5 mg. Patients treated with XELJANZ 10 mg tablets twice daily may be switched to XELJANZ XR extended-release tablets 22 mg once daily the day following the last dose of XELJANZ 10 mg.
Table 3 displays the recommended body weight-based dosages for XELJANZ tablets/XELJANZ Oral Solution and dosage adjustments for patients receiving CYP2C19 and/or CYP3A4 inhibitors [see Drug Interactions (7)], in patients with moderate or severe renal impairment, including but not limited to those undergoing hemodialysis [see Use in Specific Populations (8.7)], with moderate hepatic impairment [see Use in Specific Populations (8.8)], with lymphopenia, neutropenia, or anemia.
XELJANZ tablets/XELJANZ Oral Solution | |
---|---|
pcJIA patients |
|
Patients receiving:
[see Drug Interactions (7)] | If taking 3.2 mg twice daily, reduce to 3.2 mg once daily.
|
Patients with:
| If taking 3.2 mg twice daily, reduce to 3.2 mg once daily.
|
Patients with lymphocyte count less than 500 cells/mm3, confirmed by repeat testing | Discontinue dosing. |
Patients with ANC 500 to 1000 cells/mm3 | Interrupt dosing until ANC is greater than 1000 cells/mm3. |
Patients with ANC less than 500 cells/mm3 | Discontinue dosing. |
Patients with hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL | Interrupt dosing until hemoglobin values have normalized. |
Administer XELJANZ Oral Solution using the included press-in bottle adapter and oral dosing syringe [see Instructions for Use].
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.